Increased apolipoprotein A-I levels mediate the development of prehypertension among Turks;Artmış apolipoprotein A-I düzeyleri prehipertansiyon gelişmesine Türk yetişkinlerinde aracılık etmektedir

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 4, 2013, Pages 306-314

  Onat, Altan ^a   Can, Günay ^b   Örnek, Ender ^c   Çiçek, Gökhan ^d   Murat, Sani N ^c   Yüksel, Hüsniye ^a  

^a Department of Cardiology ^*  (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Etlik Ihtisas Educational Hospital   (Turkey)

^d Siyami Ersek Cardiovascular Surgery Center   (Turkey)

Author keywords

Apolipoproteins; C reactive protein; Diabetes type 2; Obesity; Prehypertension; Regression analysis; Systemic inflammation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PREHYPERTENSION; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TURKEY (REPUBLIC); WAIST CIRCUMFERENCE; AGE; BLOOD; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; TURKEY;

AGE FACTORS; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEX FACTORS; TURKEY;

EID: 84879267028     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.106     Document Type: Article

References (32)

1. Poirier P, Lemieux I, Mauriege P, Dewailly E, Blanchet C, Bergeron J, et al. Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 2005; 45: 363-7. [CrossRef]
2. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007; 49: 432-8. [CrossRef]
3. Tsai PS, Ke TL, Huang CJ, Tsai JC, Chen PL, Wang SY, et al. Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 23: 1355-60. [CrossRef]
4. Cordero A, Laclaustra M, Leon M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens 2006; 19: 189-96. [CrossRef]
5. Okosun IS, Boltri JM, Anochie LK, Chandra KM. Racial/ethnic differences in prehypertension in American adults: population and relative attributable risks of abdominal obesity. J Hum Hypertens 2004; 18: 849-55. [CrossRef]
6. Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects. The Bogalusa Heart Study. Hypertension 2006; 48: 33-9. [CrossRef]
7. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. Am J Hypertens 2004; 17: 568-73. [CrossRef]
8. Onat A, Yazi{dotless}ci{dotless} M, Can G, Kaya Z, Bulur S, Hergenç G. Predictive value of prehypertension for metabolic syndrome, diabetes and coronary heart disease among Turks. Am J Hypertens 2008; 21: 890-5. [CrossRef]
9. Onat A, Hergenç G, Bulur S, Uǧur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010; 142: 72-9. [CrossRef]
10. Onat A, Kömürcü-Bayrak E, Can G, Küçükdurmaz Z, Hergenç G, Erginel-Ünaltuna N. Apolipoprotein A-I positively associated with diabetes in women independently of apo E genotype and apolipoprotein B levels. Nutrition 2010; 26: 975-80. [CrossRef]
11. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism 2009; 58: 1393-9. [CrossRef]
12. Onat A, Hergenç G. Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011; 60: 499-512. [CrossRef]
13. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. [CrossRef]
14. Onat A, Şurdum-Avci{dotless} G, Şenocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidemiol Community Health 1992; 46: 470-6. [CrossRef]
15. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7. [CrossRef]
16. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 2001; 86: 5457-64. [CrossRef]
17. Onat A, Can G, Kaya H, Hergenç G. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 2010; 4: 89-98. [CrossRef]
18. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 213. [CrossRef]
19. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008; 397: 42-7. [CrossRef]
20. Sharp DS, Burchfiel CM, Rodriguez BL, Sharrett AR, Sorlie PD, Marcovina SM. Apolipoprotein A-I predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-Americans. Int J Clin Lab Res 2000; 30: 39-48. [CrossRef]
21. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDLan evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-11. [CrossRef]
22. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Ravandi A, Kuksis A. Comparative analysis of lipid composition of normal and acute phase high density lipoproteins. J Lipid Res 2000; 41: 1035-47.
23. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004; 15: 538-48. [CrossRef]
24. Geethanjali FS, Luthra K, Lingenhel A, Kanagasaba-Pathy AS, Jacob J, et al. Analysis of the apo(a) size polymorphism in Asian Indian populations: association with Lp(a) concentration and coronary heart disease. Atherosclerosis 2003; 169: 121-30. [CrossRef]
25. Nicholls SJ, Tuzcu EM, Wolski K, Bayturan O, Lavoie A, Uno K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients; insights from the PERISCOPE Study. J Am Coll Cardiol 2011; 57: 153-9. [CrossRef]
26. Guerci B, Meyer L, Sommer S, George JL, Ziegler O, Drouin P, et al. Severity of diabetic retinopathy is linked to lipoprotein(a) in type 1 diabetic patients. Diabetes Metab 1999; 25: 412-8.
27. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated with alterations of markers of insulin resistance. Hypertension 2007; 49: 1056-62. [CrossRef]
28. Shanker J, Perumal G, Rao VS, Khadrinarasimhiah NB, John S, Hebbagodi S, et al. Genetic studies on the APOAI-C3-A5 gene cluster in Asian Indians with premature coronary artery disease. Lipids Health Dis 2008; 7: 33. [CrossRef]
29. Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res 2007; 100: 299-301. [CrossRef]
30. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-7. [CrossRef]
31. The Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000. [CrossRef]
32. Onat A, Can G, Örnek E, Çiçek G, Ayhan E, Doǧan Y. Serum-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome and coronary disease. Obesity (Silver Spring) 2012; 20: 842-8. [CrossRef]